Dudediligence.

Amphastar Pharmaceuticals, Inc

AMPHNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$191.2MSep ’24$186.5MDec ’24$170.5MMar ’25$174.4MJun ’25$191.8MSep ’25$183.1MDec ’25$171.2MMar ’26$183.9MJun ’26
Net income, by quarter
$40.4MSep ’24$38.0MDec ’24$25.3MMar ’25$31.0MJun ’25$17.4MSep ’25$24.4MDec ’25$6.4MMar ’26$30.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$437.8M$499.0M$644.4M$732.0M$719.9M
Gross profit$199.7M$248.9M$351.1M$373.9M$356.1M
Operating income$69.9M$107.5M$197.0M$205.4M$140.4M
Net income$62.1M$91.4M$137.5M$159.5M$98.1M
Operating cash flow$98.0M$89.2M$183.5M$213.4M$156.1M
Free cash flow$70.5M$65.1M$145.3M$172.3M$121.2M
Cash$126.4M$156.1M$144.3M$151.6M$170.2M
Debt$77.0M$75.9M$590.0M$601.9M$621.3M
Shares outstanding47.7M48.1M48.1M47.6M45.6M